Fig. 4

Reduced activation of glial cells in the brains of 5×FAD mice after bevacizumab treatment. a Representative images of GFAP immunofluorescence staining in the hippocampus and sensory cortex of female mice. Scale bar of the hippocampus: 200 µm. Scale bar of the sensory cortex: 50 µm. b Quantitative analyses of GFAP fluorescence % area in the hippocampus and sensory cortex of female mice (n = 6–10 mice per group). c Representative images of IBA1 immunofluorescence staining in the hippocampus and sensory cortex of female mice. Scale bar of the hippocampus: 200 µm. Scale bar of the sensory cortex: 100 µm. d Quantitative analyses of IBA1 fluorescence % area in the hippocampus and sensory cortex of female mice (n = 6–10 mice per group). e Representative images of GFAP immunofluorescence staining in the hippocampus and sensory cortex of male mice. Scale bar of the hippocampus: 200 µm. Scale bar of the sensory cortex: 50 µm. f Quantitative analyses of GFAP fluorescence % area in the hippocampus and sensory cortex of male mice (n = 6–9 mice per group). g Representative images of IBA1 immunofluorescence staining in the hippocampus and sensory cortex of male mice. Scale bar of the hippocampus: 200 µm. Scale bar of the sensory cortex: 100 µm. h Quantitative analyses of IBA1 fluorescence % area in the hippocampus and sensory cortex of male mice (n = 6–9 mice per group). All data are presented as the mean ± SEM and were analyzed by one-way ANOVA followed by Fisher’s LSD test. WT (Veh): wild-type littermates receiving sham treatment, AD (Veh): 5×FAD mice receiving sham treatment, AD (Bev): 5×FAD mice receiving bevacizumab treatment